Skip to main content

Table 1 Clinical characteristics of participants with Juvenile idiopathic arthritis (JIA) in relation to temporomandibular disorder (TMD)

From: Prevalence of temporomandibular disorder in children and adolescents with juvenile idiopathic arthritis – a Norwegian cross- sectional multicentre study

  Total cohort TMD No TMD
n = 221 n = 88 n = 133
Value Value Value
Girls, n (%) 132 (59.7) 61 (69.3) 71 (53.4)
Age at onset, median (IQR) 6.1 (8.1, 2.3–10.4) 6.8 (8.4, 0.7–14.2) 5.2 (7.2, 0.9–14.7)
Age at visit by paediatric rheumatologists at the hospital, median (IQR) 12.7 (5.3, 9.4–14.7) 13.1 (3.3, 5.2–16.1) 11.7 (6.5, 4.8–16.5)
Disease duration, median (IQR) 4.6 (5.7, 2.6–8.3) 4.6 (6.0, 0.2–14.2) 4.6 (5.5, 0.2–14.7)
JIA categories, n (%)
 Oligoarthritis persistent 77 (34.8) 27 (30.7) 50 (37.6)
 Oligoarthritis extended 21 (9.5) 11 (12.5) 10 (7.5)
 Systemic arthritis 7 (3.2) 2 (2.3) 5 (3.8)
 RF negative polyarthritis 49 (22.2) 17 (19.3) 32 (24.1)
 RF positive polyarthritis 4 (1.8) 2 (2.3) 2 (1.5)
 Psoriatic arthritis 9 (4.1) 6 (6.8) 3 (2.3)
 Enthesitis-related arthritis 23 (10.4) 9 (10.2) 14 (10.5)
 Undifferentiated JIA 31 (14.0) 14 (15.9) 17 (12.8)
Ongoing medication, n (%)
 No DMARDs 75 (33.9) 26 (11.8) 49 (22.2)
 sDMARDs*  60 (27.1)  23 (10.4) 37 (16.7)
 bDMARDs**  86 (38.9) 39 (17.6) 47 (21.3)
  1. JIA Juvenile idiopathic arthritis, TMD Temporomandibular disorder
  2. *sDMARDs = Synthetic disease-modifying antirheumatic- drugs; methotrexate, mykofenolatmofetil, **bDMARDs = Biologic disease-modifying antirheumatic-drugs; etanercept, infliximab, adalimumab, tocilizumab, abatacept, certolizumab, golimumab